The Scientist

» drug development, disease/medicine and culture

Most Recent

image: Thirty Years of Lab Safety

Thirty Years of Lab Safety

By | October 1, 2016

From mouth pipetting to automated liquid handling, life-science labs have gotten much safer over the past three decades.

1 Comment

image: Genes Linked to Dogs’ Sociability with People

Genes Linked to Dogs’ Sociability with People

By | September 30, 2016

Genetic variants on chromosome 26 appears to play a role in a dog’s tendency to turn to people for help.

0 Comments

image: Does Productivity Diminish Research Quality?

Does Productivity Diminish Research Quality?

By | September 28, 2016

More papers correlate with top-cited research for more-established academics, but not newly minted professors, according to a study.  

3 Comments

image: Broadly Neutralizing Antibodies in HIV Patients

Broadly Neutralizing Antibodies in HIV Patients

By | September 28, 2016

Researchers identify aspects of the patient, the virus, and the infection itself that influence whether a person with HIV will produce broadly neutralizing antibodies.

0 Comments

image: Q&A: From FDA to Industry

Q&A: From FDA to Industry

By | September 27, 2016

Among a subset of US Food and Drug Administration regulators who leave the agency, more than half go to work for pharmaceutical companies, researchers report.

1 Comment

The National Institutes of Health is hosting a two-day conference on how the virus affects infants and children. The take-home message so far: microcephaly is but one of many potential problems for Zika-exposed fetuses.

0 Comments

image: Allergan’s Buying Spree Rolls On

Allergan’s Buying Spree Rolls On

By | September 21, 2016

The Ireland-based pharma company makes a $1.7 billion offer to acquire Tobira Therapeutics, a US firm developing liver disease drugs.

0 Comments

image: Feds Demand More Clinical Trial Reporting

Feds Demand More Clinical Trial Reporting

By | September 19, 2016

Expanded US Health and Human Services rules will require the results of more human studies to be made public.

1 Comment

Scientists estimate the risk to fetuses exposed to the virus in utero.

0 Comments

image: Allergan Set to Buy Vitae

Allergan Set to Buy Vitae

By | September 16, 2016

The Irish drugmaker has made a $639 million dollar offer to buy the US-based biopharma.

0 Comments

Popular Now

  1. Broad Wins CRISPR Patent Interference Case
    Daily News Broad Wins CRISPR Patent Interference Case

    The USPTO’s Patent Trial and Appeal Board has ruled in favor of the Broad Institute of MIT and Harvard retaining intellectual property rights covered by its patents for CRISPR gene-editing technology.

  2. Henrietta Lacks’s Family Seeks Compensation
  3. Humans Never Stopped Evolving
    Features Humans Never Stopped Evolving

    The emergence of blood abnormalities, an adult ability to digest milk, and changes in our physical appearance point to the continued evolution of the human race.

  4. Abundant Sequence Errors in Public Databases
Business Birmingham